H1Z Stock Overview

A clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. More details

H1Z fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 99.8% below our estimate of its fair value

Risk Analysis

Has less than 1 year of cash runway

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue ($0)

Does not have a meaningful market cap (€26M)

+ 2 more risks

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

NeuroSense Therapeutics Ltd. Competitors

4SC

DB:VSC

€30.5m

2invest

XTRA:2INV

€69.5m

co.don

XTRA:CNW

€6.5m

Heidelberg Pharma

XTRA:HPHA

€147.7m

Price History & Performance

Summary of share price highs, lows and changes for NeuroSense Therapeutics
Historical stock prices
Current Share Price	US$0.95
52 Week High	US$0.97
52 Week Low	US$0.79
Beta	1.34
1 Month Change	13.83%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-0.52%

Recent updates

Shareholder Returns

	H1Z	DE Biotechs	DE Market
7D	5.4%	-0.9%	1.4%
1Y	n/a	-12.8%	13.8%

Return vs Industry: Insufficient data to determine how H1Z performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how H1Z performed against the German Market.

Price Volatility

Is H1Z's price volatile compared to industry and market?
H1Z volatility
H1Z Average Weekly Movement	9.1%
Biotechs Industry Average Movement	5.7%
Market Average Movement	6.4%
10% most volatile stocks in DE Market	12.9%
10% least volatile stocks in DE Market	3.1%

Stable Share Price: H1Z's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine H1Z's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2017	17	Alon Ben-Noon	www.neurosense-tx.com

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer’s disease.

NeuroSense Therapeutics Ltd. Fundamentals Summary

How do NeuroSense Therapeutics's earnings and revenue compare to its market cap?
H1Z fundamental statistics
Market cap	€23.58m
Earnings (TTM)	-€9.12m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-3.0x

P/E Ratio

Is H1Z overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
H1Z income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$10.21m
Earnings	-US$10.21m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.43
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did H1Z perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/13 19:29
End of Day Share Price	2025/05/13 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NeuroSense Therapeutics Ltd. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
James Molloy	Alliance Global Partners
Jason Kolbert	D. Boral Capital LLC.
Nazibur Rahman	Maxim Group

NeuroSense Therapeutics DB:H1Z Stock Report